CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes

• Published in: Haematologica (Roma) 2013-02, Vol.98 (2), p.274-278
• Main Authors: Gonzalez, David, Else, Monica, Wren, Dorte, Usai, Monica, Buhl, Anne Mette, Parker, Anton, Oscier, David, Morgan, Gareth, Catovsky, Daniel
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Female; Gene Expression; Humans; Immunoglobulin Heavy Chains - genetics; Immunoglobulin Variable Region - genetics; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - genetics; Leukemia, Lymphocytic, Chronic, B-Cell - mortality; Male; Middle Aged; Mutation; Neoplasm Proteins - genetics; Prognosis; RNA, Long Noncoding; Treatment Outcome
• ISSN: 0390-6078; 1592-8721
• DOI: 10.3324/haematol.2012.070201

CLLU1, located at chromosome 12q22, encodes a transcript specific to chronic lymphocytic leukemia and has potential prognostic value. We assessed the value of CLLU1 expression in the LRF CLL4 randomized trial. Samples from 515 patients with chronic lymphocytic leukemia were collected immediately before the start of treatment. After RNA extraction and cDNA synthesis, CLLU1 expression was assessed by quantitative polymerase chain reaction. In total, 247 and 268 samples were identified as having low and high CLLU1 expression, respectively. The median follow-up was 88 months. High CLLU1 expression was significantly correlated with unmutated IGHV genes, ZAP-70 and CD38 positivity, and absence of 13q deletion (all r>0.2, P